Bio-Thera Solutions Future Growth
Future criteria checks 3/6
Bio-Thera Solutions is forecast to grow earnings and revenue by 2.9% and 24% per annum respectively. EPS is expected to grow by 3.1% per annum. Return on equity is forecast to be 41.9% in 3 years.
Key information
2.9%
Earnings growth rate
3.1%
EPS growth rate
| Biotechs earnings growth | 43.1% |
| Revenue growth rate | 24.0% |
| Future return on equity | 41.9% |
| Analyst coverage | Low |
| Last updated | 19 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,773 | N/A | 655 | 1,430 | 2 |
| 12/31/2025 | 1,784 | -395 | 72 | 598 | 2 |
| 12/31/2024 | 946 | -474 | -382 | -218 | 2 |
| 9/30/2024 | 825 | -378 | -317 | -186 | N/A |
| 6/30/2024 | 792 | -378 | -520 | -305 | N/A |
| 3/31/2024 | 711 | -371 | -593 | -380 | N/A |
| 12/31/2023 | 705 | -395 | -723 | -461 | N/A |
| 9/30/2023 | 534 | -607 | -780 | -504 | N/A |
| 6/30/2023 | 541 | -565 | -813 | -513 | N/A |
| 3/31/2023 | 536 | -513 | -828 | -502 | N/A |
| 12/31/2022 | 455 | -480 | -672 | -413 | N/A |
| 9/30/2022 | 803 | -62 | -135 | 102 | N/A |
| 6/30/2022 | 737 | -90 | 176 | 304 | N/A |
| 3/31/2022 | 850 | 81 | 215 | 302 | N/A |
| 12/31/2021 | 837 | 82 | 158 | 236 | N/A |
| 9/30/2021 | 492 | -263 | -226 | -135 | N/A |
| 6/30/2021 | 463 | -267 | -442 | -305 | N/A |
| 3/31/2021 | 223 | -513 | -494 | -326 | N/A |
| 12/31/2020 | 183 | -513 | -611 | -358 | N/A |
| 9/30/2020 | 106 | -501 | -693 | -469 | N/A |
| 6/30/2020 | 49 | -551 | -659 | -478 | N/A |
| 3/31/2020 | 20 | -600 | -698 | -550 | N/A |
| 12/31/2019 | 1 | -1,023 | -673 | -598 | N/A |
| 9/30/2019 | 1 | -1,075 | -1,032 | -649 | N/A |
| 12/31/2018 | N/A | -553 | -846 | -528 | N/A |
| 12/31/2017 | 2 | -236 | N/A | -237 | N/A |
| 12/31/2016 | 3 | -137 | N/A | -116 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688177 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 688177 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 688177 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 688177's revenue (24% per year) is forecast to grow faster than the CN market (13.8% per year).
High Growth Revenue: 688177's revenue (24% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688177's Return on Equity is forecast to be very high in 3 years time (41.9%).